The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.
about
Resistance to antiplatelet drugs: current status and future researchSuspected clopidogrel resistance in a patient with acute stent thrombosisEvidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'Aspirin and clopidogrel resistance: consideration and managementStent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapyClopidogrel: the data, the experience, and the controversies.Antiplatelet and anticoagulant drugs in interventional radiology.Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.Clopidogrel "resistance": where are we now?Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointerventionParaoxonase 1 (PON1) gene variants are not associated with clopidogrel response.Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.Peri-procedural myocardial injury: 2005 update.AZD6140.Clopidogrel resistance--the cardiologist's perspective.Aspirin and clopidogrel response variability: review of the published literatureAntiplatelet therapy in the era of drug-eluting stents: current and future perspectives.Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularizationInitiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study.Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention.Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the WoAspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention.Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.Recent developments in clopidogrel pharmacology and their relation to clinical outcomes.Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonistP2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence.Platelet reactivity and nonresponse to dual antiplatelet therapy: a review.Prasugrel: a critical comparison with clopidogrel.Personalized antiplatelet therapy for coronary artery disease patients: is this the future?Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease.Dosing strategies for antiplatelet therapy in percutaneous coronary intervention.Antiplatelet therapy in acute coronary syndromes.Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention.Low stent thrombosis risk with the XIENCE V® Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials.Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention.Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.
P2860
Q28192298-0DD4FDB4-AAC8-4E0B-A62E-27D7DE7DDF68Q28196159-160D1F96-2DD7-4A33-8EC3-133124CEF36EQ28200552-0629B01F-AD73-4F76-9320-BFED8F36D495Q28200610-C37C98C3-7B9E-42B6-935F-094B86329397Q28218066-44699E6F-89E5-4658-B25F-1327A1DB9AEEQ30573045-901050FA-A7D4-40EB-83AC-A47E070D88ACQ33395898-B8D422D3-F69B-4FEC-80C7-9075D0505AB4Q33933475-852ED623-A25E-47B6-82C7-8BB6D6AC7CE7Q34212563-9E782FD4-6535-4EC1-B8A1-C404F35EC872Q34316378-17E7F310-BC4F-4607-A726-1669D18E2DA0Q35648335-A41D1021-F9C3-4394-8E06-C36D682FC38EQ35683705-25D1D389-41DF-43FC-9FD1-DCEB853AF031Q36263844-5D7E419D-31D7-4C53-AFBE-735502AE99DCQ36715768-08AA17DE-5DCF-4151-95E7-E2CC1BFE41AAQ36819608-D346A8F3-415F-4B1D-857D-47FC97B6297CQ36932221-679F2088-BEDB-4106-8A9B-A285DC2C2AEEQ36941850-3A5EA762-4C6C-4A39-A249-D6F96520038AQ37067222-ACD74B5A-52CC-46CD-8D0E-E62E81C3D209Q37076393-7EF32D15-33D6-48AA-88CB-4821F83220B3Q37167506-EF7B5F3D-5700-42BB-AF3D-5D0015742FBDQ37175783-B54EE68D-10A1-4E47-9CDB-42CD5445286FQ37268748-C8C6C1B3-4942-4874-9D51-2CF9CF3FFC12Q37378896-CEAA0A0C-C8C6-4DB7-8BA4-CBB93DF090CBQ37458916-19F01330-5BA9-4D40-9527-41975DA92B86Q37479082-D130566C-5FA1-4D66-A0DB-C20B3C2014F7Q37486601-89A9B0C6-1B1F-41CF-BA4D-97300192F782Q37540088-D31CD1A1-465A-4696-B276-1E10B4314228Q37552005-15B1946B-48E5-42A1-B16C-9C46122598A6Q37562606-47EB79A9-5E8E-4B4D-8D17-534489363AD1Q37608580-D4398E90-166C-4390-B552-3714A29109FFQ37618798-4612A2EA-FBB0-4EDF-8D21-13B30B56FBA4Q37641320-FE741560-CA13-41E4-B330-1AE849E8ECEFQ37642822-6D0A857A-E4B8-46F8-9A4D-DA01D45D6F5FQ37749813-F560E7B3-ED2B-4AE6-B0BF-0AF807B2C6ECQ37752222-AA406EDC-9B13-436F-AF7E-9674B49299ECQ37798110-D1DB0BF1-7F5F-4893-BE79-5CD1BD84808FQ37841560-B6AD677F-A2D9-4AE3-BA96-F5192E796F0BQ37858604-3085E033-F6A7-420E-918F-4344B56FE0D8Q37880741-042657FE-6F9B-460C-A137-8EEFBC7B27F9Q37882712-8AF4BEA6-3AD1-4CD2-9478-9AAD54317860
P2860
The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The relation of dosing to clop ...... undergoing coronary stenting.
@en
The relation of dosing to clop ...... undergoing coronary stenting.
@nl
type
label
The relation of dosing to clop ...... undergoing coronary stenting.
@en
The relation of dosing to clop ...... undergoing coronary stenting.
@nl
prefLabel
The relation of dosing to clop ...... undergoing coronary stenting.
@en
The relation of dosing to clop ...... undergoing coronary stenting.
@nl
P2093
P1476
The relation of dosing to clop ...... undergoing coronary stenting.
@en
P2093
Jason A Yoho
Kevin M Hayes
Kevin P Bliden
Paul A Gurbel
Udaya S Tantry
William R Herzog
P304
P356
10.1016/J.JACC.2005.01.030
P407
P577
2005-05-01T00:00:00Z